FindTrial
Sign In

The Role of Interferon-Induced Protein 44-Like (IFI44L) Promoter Methylation in the Early Diagnosis and Disease Activity Assessment of Takayasu Arteritis

Takayasu arteritis patients; Interferon-inducible protein 44-like (IFI44L) promoter methylation; Diagnosis and disease activity assessment; Prospective multicenter database study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500115680
Enrollment
Unknown
Registered
2025-12-30
Start date
2026-01-01
Completion date
Unknown
Last updated
2026-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with Takayasu Arteritis

Interventions

Takayasu Arteritis Group:None
Atherosclerosis Group:None
Healthy contral:None

Sponsors

Beijing Anzhen Hospital, Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Healthy Control Group: Age- and sex-matched healthy individuals. 2. Atherosclerosis (AS) Control Group: Patients with a confirmed diagnosis of atherosclerosis. 3. Takayasu Arteritis (TAK) Group: Patients meeting the diagnostic criteria for TAK. All participants will provide written informed consent. 4. Inclusion criteria: Age 18–75 years.

Exclusion criteria

Exclusion criteria: 1. Coexisting autoimmune diseases; 2. Severe hepatic or renal dysfunction; 3. Active infection or active tuberculosis; 4. Malignancy; 5. Pregnancy; 6. Significant thyroid dysfunction; 7. Incomplete clinical data.

Design outcomes

Primary

MeasureTime frame
Interferon-Induced Protein 44-Like (IFI44L) Promoter Methylation;—

Secondary

MeasureTime frame
erythrocyte sedimentation rate;c-reactive protein;—

Countries

China

Contacts

Public ContactLili Pan

Beijing Anzhen Hospital, Capital Medical University

lilypansxmu@sina.com+86 137 2002 1786

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026